These recommended abstracts have been selected by Robert A. Figlin, MD, Editor-in-
Chief of the Kidney Cancer Journal. The chosen abstracts provided here highlight some of the most important trends in ongoing trials and reﬂect
the foremost research and strategies from latest clinical trials that
impact the current standard of care in renal cancer.
Final overall survival analysis and organ-specific target lesion assessments with two-year follow-up in CheckMate 9ER:
Nivolumab plus cabozantinib versus sunitinib for patients with advanced renal cell carcinoma.
TiNivo-2: A phase 3, randomized, controlled, multicenter, open-label study to compare tivozanib
in combination with nivolumab to tivozanib monotherapy in subjects with renal cell carcinoma
who have progressed following one or two lines of therapy where one line has an immune checkpoint inhibitor..